ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Phathom Pharmaceuticals, Inc. Develops and commercializes treatments for acid-related gastrointestinal diseases.	United States of America	PHAT
Pherecydes Pharma Develops precision phage therapy to treat resistant bacterial infections.	France	ALPHE
PHIBRO ANIMAL HEALTH CORP Develops animal health products, vaccines, and nutrition for livestock and companion animals.	United States of America	PAHC
Philogen Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.	Italy	PHIL
Phio Pharmaceuticals Corp. Developing RNAi-based immuno-oncology therapeutics for melanoma and other skin cancers.	United States of America	PHIO
Phoenix Asia Holdings Ltd A subcontractor for substructure projects and a large-scale manufacturer of fine chemicals & APIs.	United States of America	PHOE
Photocure ASA Develops photodynamic pharmaceuticals and devices to enhance bladder cancer detection for urologists.	Norway	PHO
Pierrel Global pharma company specializing in dental anesthetics and contract manufacturing services.	Italy	PRL
PLIANT THERAPEUTICS, INC. Developing novel integrin-based therapies for fibrosis and related diseases.	United States of America	PLRX
Plumbline Life Sciences, Inc. Develops DNA vaccines and therapeutics for companion animals and livestock.	South Korea	222670